Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates

Simple item page
dc.contributor.authorWarren, Ronald
dc.contributor.authorWong, Michael
dc.contributor.authorMelcher, Gregory
dc.contributor.authorBlatt, Stephen
dc.contributor.authorCahn, Pedro
dc.contributor.authorPerez, Héctor
dc.contributor.authorZapiola, Inés
dc.contributor.authorBouzas, María Belén
dc.contributor.authorMuchinik, Guillermo
dc.contributor.authorAnderson, Stephanie
dc.contributor.authorKennedy, Ronald
dc.date.accessioned2024-05-23T23:49:24Z
dc.date.available2024-05-23T23:49:24Z
dc.date.issued1995-02
dc.descriptionFil: Cahn, P. Fundación Huésped. Ciudad Autónoma de Buenos Aires; Argentina.es_ES
dc.description.abstractThis study examined serum specimens from HIV-1 infected individuals from Argentina (n = 50) and the United States (n = 38) for antibody reactivity to a panel of V3-based synthetic peptides. Serum specimens were further analyzed for the ability to neutralize laboratory and clinical isolates of HIV-1 in vitro. Patterns of antibody reactivity to these V3 peptides, together with neutralizing activity, indicated that infected individuals from both Argentina and the US have been exposed to HIV-1 isolates belonging to subgroup B. Serum specimens from the United States (37 males and 1 female) were obtained from military personnel and their dependents. Of these patients, 35 were asymptomatic and 3 were symptomatic. Specimens from Argentina were obtained from HIV-1-infected individuals examined in Buenos Aires, Argentina (37 males and 13 females). Half of the infected individuals from Argentina were symptomatic. Serum specimens were screened for antibody reactivity to HIV-1 gp160 synthetic peptides by an enzyme-linked immunosorbent assay. Examination of V3 peptide recognition indicated that a higher percentage of Argentinean serum specimens reacted with peptide RP189 than serum specimens from the United States (34% and 5%, respectively). A higher percentage of serum specimens from the United States reacted with peptide RP135 (LAI) than was observed with serum specimens from Argentina (47% vs. 16%, respectively). Neutralization assays again indicated a similar pattern of antibody reactivity with serum specimens from infected individuals from Argentina and the United States. Nucleotide sequence analysis of clinical isolates has demonstrated that the HIV-1 subgroup B is predominant in the United States. Serologic reactivity to V3-based peptides in this study suggests that isolates commonly found in the US (i.e., MN, SF2, and NY-5) are also frequently observed in Argentina. These results suggest that there is similar distribution of HIV-1 subgroup B isolates among infected individuals from Argentina and the United States.es
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1128/jcm.33.2.481-483.1995
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1350
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesJ Clin Microbiol.;1995 33(2): 481-3
dc.rightsopenAccesses_ES
dc.subjectSíndrome de Inmunodeficiencia Adquiridaes_ES
dc.subjectVIH-1es_ES
dc.subjectEstados Unidoses_ES
dc.subjectArgentinaes_ES
dc.titleSerologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolateses_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1128jcm3324814831995_eng.pdf
Size:
145.5 KB
Format:
Adobe Portable Document Format
Description:
Inglés; 3 páginas
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos